A5003934797- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Viral Infectious Diseases and Gene Expression in Insects
- Synthesis and Biological Activity
- Gastrointestinal motility and disorders
- Monoclonal and Polyclonal Antibodies Research
- Evolution and Genetic Dynamics
- T-cell and B-cell Immunology
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Signaling Pathways in Disease
- Therapeutic Uses of Natural Elements
- Blood disorders and treatments
- Cancer Mechanisms and Therapy
- Complementary and Alternative Medicine Studies
- Diabetes Treatment and Management
Universitätsklinikum Würzburg
2019-2025
Central South University
2024
University of Würzburg
2021
Abstract The definition of high‐risk (HR) multiple myeloma (MM) is still a matter debate. We prospectively evaluated the HR detection using FISH in combination with SKY92 gene expression profiling 258 MM patients (newly diagnosed [ND] MM: n = 109; relapsed/refractory [RR] 149). was significantly enriched RRMM (57/121, 47.1%) compared NDMM (17/95, 17.9%) ( p < 0.0001). showed shorter progression‐free survival (PFS) 0.0001) and overall (OS) than standard‐risk (SR). In NDMM, also indicated...
<title>Abstract</title> Extramedullary multiple myeloma (EMD) is associated with low response rates, short progression-free survival and poor prognosis. CAR T cells bispecific antibodies (bsABs) have shown efficacy in relapsed but it remains uncertain whether one cell redirection strategy should be preferred. We retrospectively analyzed 80 patients EMD not adjacent to the bone treated ide-cel, cilta-cel, teclistamab or talquetamab at three academic centers Germany. All were heavily...
Multiple myeloma is a hematological malignancy that has evolved from antibody-secreting B lymphocytes. Like other types of cancers, cells have acquired functional capabilities which are referred to as "Hallmarks Cancer", and one their most important features the metabolic disorders. Due high secretory load MM cells, first-line medicine proteasome inhibitors found pronounced effects in for blocking degradation misfolded proteins, leading accumulation ER overwhelming stress. Moreover, been...
Summary Biomarkers for cytopenias following CAR T‐cell treatment in relapsed/refractory (RR) multiple myeloma (MM) are not completely defined. We prospectively analysed 275 sequential peripheral blood (PB) samples from 58 RRMM patients treated with BCMA‐targeted T cells, and then divided them into three groups: (i) baseline (before leukapheresis), (ii) ≤day+30, (iii) >day+30 after therapy. evaluated laboratory data performed flow cytometry to determine the (CAR) subsets. Baseline...
Abstract Multiple myeloma (MM) is a genetically heterogeneous disease and the management of relapses one biggest clinical challenges. TP53 alterations are established high‐risk markers included in current staging criteria. KRAS most frequently mutated gene affecting around 20% MM patients. Applying Clonal Competition Assays (CCA) by co‐culturing color‐labeled modified cell models, we recently showed that mono‐ biallelic transmit fitness advantage to cells. Here, report similar dynamic for...
In this study we aimed to assess the prevalence of functional bowel disorders (FBD) in a group Chinese first-year undergraduates and association between common beverage intake FBD.A cross-sectional survey was conducted among Huazhong University Science Technology (Wuhan, Hubei Province, China). total, 3102 questionnaires on their lifestyle, dietary habits gastrointestinal symptoms were collected analyzed. FBD diagnosed based Rome IV criteria. A logistic regression analysis performed compare...
<p>Cell survival of DNMTi pretreated KMS11 cells under BTZ exposure. AlamarBlue assay after 72 hours incubation with varying concentrations (0.5 nM to 4 nM) on (48 h 500 Aza, 100 Dec) and PI naïve KMS11. No resensitizing effect treatment was observed.</p>
<p>Patient-derived mutations impair PI response to Carfilzomib and Ixazomib. Cytotoxicity assay IC50 values of RPMI-8226 MM cell lines harboring two different stably expressed patient-derived in proteasome subunits. The mutants were more resistant the inhibitors Ixazomib compared controls (*) lentivirally-encoded WT sequence PSMC6/PSMD1. Shown are means standard deviations three independent experiments (biological replicates) technical replicates each experiment. PSMC6 PSMD1 expression...
<p>Quality check of DBS assays with artificially methylated standard DNAs. DNA standards 0%, 25%, 50%, 75% and 100% methylation were sequenced the PSMB5, PSMC2, PSMC5, PSMC6, PSMD1 PSMD5 to confirm assay sensitivity. Results for all investigated amplicons correlated well expected curves (P < 0.001) (A). The sequencing depths was 10-3 (B).</p>
<p>DNA promoter methylation of a subset proteasome subunit genes. Heatmap comparing pattern 35 MM patients and 30 PBMC samples. The degree is given by color code: red – methylated state, blue unmethylated state. Each line represents an individual sample, each column single CpG. encoded with for Artificially controls were included. For PSMD5, hypermethylation was only present in cells, not PBMCs. PSMC2, occurred both, cells PBMCs, indicating physiological state probably independent...
<p>Cell survival of DNMTi pretreated KMS11 cells under BTZ exposure. AlamarBlue assay after 72 hours incubation with varying concentrations (0.5 nM to 4 nM) on (48 h 500 Aza, 100 Dec) and PI naïve KMS11. No resensitizing effect treatment was observed.</p>